Pharmacokinetic‐pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus
This modelling assessment was successfully applied for cotadutide to understand the relationship between cotadutide dosing regimen and the response in UACR, UALB and body weight. These models have general application in analysing and interpreting data from CKD/diabetic kidney disease (DKD) studies.
Authors
- Viknesh Selvarajah (ORCID: https://orcid.org/0000-0003-3473-4005)
- Victoria Parker (ORCID: https://orcid.org/0000-0003-2706-2669)
- Darren Robertson
- Bengt Hamrén (ORCID: https://orcid.org/0000-0001-5002-3399)
- Hongtao Yu (ORCID: https://orcid.org/0000-0003-2278-4478)
- Anis A. Khan (ORCID: https://orcid.org/0000-0001-8262-3022)
- Joanna Parkinson (ORCID: https://orcid.org/0000-0003-4492-5243)
- Lars Hansen
Institutions
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-05-09
- DOI
- https://doi.org/10.1002/bcp.70093
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- AstraZeneca